NCT06228066View on ClinicalTrials.gov

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 13, 2024

Primary Completion Date

September 1, 2027

Study Completion Date

September 1, 2028

Conditions
Small Cell Carcinoma of the BladderHigh Grade Neuroendocrine Tumors of the Urinary Tract
Interventions
DRUG

Lurbinectedin

Lurbinectedin is administered IV over 1 hour at 3.2 mg/m2 on day 1 of each 21-day cycle

DRUG

Avelumab

Avelumab is administered IV at 800 mg over 1 hour on day 1 of each 21-day cycle

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH